Discussing Risankizumb, Differences in IL-23 Inhibitor Epitopes with Christopher Bunick, MD, PhD скачать в хорошем качестве

Discussing Risankizumb, Differences in IL-23 Inhibitor Epitopes with Christopher Bunick, MD, PhD

There is an increasing focus on the importance of interleukin (IL)-23 to the pathogenesis of plaque psoriasis and psoriatic disease in general within the dermatology research space. This topic of interest was explored recently in a study titled ‘Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis,’ with one of the study’s authors being Yale School of Medicine associate professor Christopher Bunick, MD, PhD. Bunick spoke to the HCPLive editorial team in this interview about his team’s findings and their implications. #Dermatology #Psoriasis https://www.hcplive.com/view/discussi...